Clinical Trials
9 trialsNCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07247227 2025-11-25
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Peking Union Medical College
Phase NA Recruiting
NCT07134413 2025-08-21
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT06893354 2025-03-25
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
The First Affiliated Hospital of Guangzhou Medical University
Phase 4 Not yet recruiting
NCT06746870 2024-12-24
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 2 Not yet recruiting
NCT06479759 2024-06-28
ACCLAIM
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT05286957 2023-03-17
Seagull
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT05209256 2022-01-26
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2/3 Unknown
NCT03986528 2021-02-23
Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 4 Unknown